Conleth G. Murphy

2.1k total citations · 2 hit papers
55 papers, 1.5k citations indexed

About

Conleth G. Murphy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Conleth G. Murphy has authored 55 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 13 papers in Reproductive Medicine. Recurrent topics in Conleth G. Murphy's work include HER2/EGFR in Cancer Research (16 papers), Ovarian cancer diagnosis and treatment (13 papers) and Cancer Treatment and Pharmacology (9 papers). Conleth G. Murphy is often cited by papers focused on HER2/EGFR in Cancer Research (16 papers), Ovarian cancer diagnosis and treatment (13 papers) and Cancer Treatment and Pharmacology (9 papers). Conleth G. Murphy collaborates with scholars based in Ireland, United States and Spain. Conleth G. Murphy's co-authors include Maura N. Dickler, Andrew D. Seidman, Patrick G. Morris, Mary Ellen Moynahan, Shanu Modi, Jason Konner, Ana Oaknin, Domenica Lorusso, Nicoletta Colombo and Monica Fornier and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Conleth G. Murphy

53 papers receiving 1.4k citations

Hit Papers

Efficacy and Safety of Mirvetuximab Soravtansine in ... 2021 2026 2022 2024 2023 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
    2023 220 citations Ursula A. Matulonis, Domenica Lorusso et al. Journal of Clinical Oncology profile →
  2. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
    2021 186 citations Kathleen N. Moore, Amit M. Oza et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Conleth G. Murphy Ireland 19 1.0k 430 322 282 218 55 1.5k
Véronique D’Hondt France 21 781 0.8× 335 0.8× 298 0.9× 276 1.0× 241 1.1× 83 1.3k
Mayu Yunokawa Japan 25 1.1k 1.1× 482 1.1× 511 1.6× 256 0.9× 373 1.7× 140 2.1k
Henrik Roed Denmark 22 755 0.7× 525 1.2× 309 1.0× 333 1.2× 119 0.5× 56 1.8k
Sharad Ghamande United States 22 770 0.8× 230 0.5× 579 1.8× 476 1.7× 216 1.0× 114 1.7k
Volker Möbus Germany 26 1.2k 1.2× 312 0.7× 493 1.5× 422 1.5× 587 2.7× 117 2.2k
Antonio Febbraro Italy 18 649 0.6× 314 0.7× 249 0.8× 174 0.6× 241 1.1× 56 1.2k
Andrea Michelotti Italy 17 746 0.7× 240 0.6× 187 0.6× 343 1.2× 263 1.2× 60 1.3k
Kathy Han Canada 22 865 0.8× 459 1.1× 772 2.4× 268 1.0× 343 1.6× 102 2.7k
Gregory Friberg United States 18 722 0.7× 318 0.7× 504 1.6× 144 0.5× 269 1.2× 35 1.2k
Akihiko Shimomura Japan 22 1.1k 1.1× 536 1.2× 751 2.3× 81 0.3× 537 2.5× 132 2.0k

Countries citing papers authored by Conleth G. Murphy

Since Specialization
Citations

This map shows the geographic impact of Conleth G. Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conleth G. Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conleth G. Murphy more than expected).

Fields of papers citing papers by Conleth G. Murphy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conleth G. Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conleth G. Murphy. The network helps show where Conleth G. Murphy may publish in the future.

Co-authorship network of co-authors of Conleth G. Murphy

This figure shows the co-authorship network connecting the top 25 collaborators of Conleth G. Murphy. A scholar is included among the top collaborators of Conleth G. Murphy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Conleth G. Murphy. Conleth G. Murphy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coleman, Robert L., Domenica Lorusso, Ana Oaknin, et al.. (2024). Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. International Journal of Gynecological Cancer. 34(8). 1119–1125. 11 indexed citations
2.
Lorusso, Domenica, Ana Oaknin, Amit M. Oza, et al.. (2024). Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary. Gynecologic Oncology. 191. 249–258. 8 indexed citations
3.
Matulonis, Ursula A., Domenica Lorusso, Ana Oaknin, et al.. (2023). Reply to Z.R. McCaw et al. Journal of Clinical Oncology. 41(29). 4705–4706. 2 indexed citations
4.
Matulonis, Ursula A., Domenica Lorusso, Ana Oaknin, et al.. (2023). Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. Obstetrical & Gynecological Survey. 78(6). 343–344. 4 indexed citations
5.
Matulonis, Ursula A., Domenica Lorusso, Ana Oaknin, et al.. (2023). Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. Journal of Clinical Oncology. 41(13). 2436–2445. 220 indexed citations breakdown →
6.
7.
8.
McCracken, Stephen, et al.. (2019). The Need for Increased Melanoma Awareness among Non-dermatology Secondary Care Colleagues. Acta Dermato Venereologica. 99(7). 693–694. 3 indexed citations
9.
Murphy, Conleth G.. (2019). The Role of CDK4/6 Inhibitors in Breast Cancer. Current Treatment Options in Oncology. 20(6). 52–52. 40 indexed citations
10.
Mihai, Alina, John Armstrong, Mary Dunne, et al.. (2017). Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease.. Lenus, The Irish Health Repository (Dr Steevens Hospital Library). 5(1). 43–53. 9 indexed citations
11.
Kelly, Catherine M., John McCaffrey, Michelle L. Smith, et al.. (2017). Do oncology patients understand clinical trials? A nationwide study by Cancer Trials Ireland. Annals of Oncology. 28. v643–v644. 6 indexed citations
12.
Ito, Shuhei, Conleth G. Murphy, Ekaterina Doubrovina, Maria Jasin, & Mary Ellen Moynahan. (2016). PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells. PLoS ONE. 11(7). e0159341–e0159341. 30 indexed citations
13.
Murphy, Conleth G. & Maura N. Dickler. (2016). Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocrine Related Cancer. 23(8). R337–R352. 94 indexed citations
14.
Peereboom, D., Conleth G. Murphy, Manmeet S. Ahluwalia, et al.. (2014). Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro-Oncology. 16(4). 579–583. 22 indexed citations
15.
Morris, Patrick G., Conleth G. Murphy, Divya Mallam, et al.. (2012). Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. The Breast Journal. 18(4). 345–350. 32 indexed citations
16.
Murphy, Conleth G. & Patrick G. Morris. (2012). Recent advances in novel targeted therapies for HER2-positive breast cancer. Anti-Cancer Drugs. 23(8). 765–776. 56 indexed citations
17.
Brogi, Edi, Conleth G. Murphy, Matthew Johnson, et al.. (2011). Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Annals of Oncology. 22(12). 2597–2603. 30 indexed citations
18.
Murphy, Conleth G. & Monica Fornier. (2010). HER2-positive breast cancer: beyond trastuzumab.. PubMed. 24(5). 410–5. 31 indexed citations
19.
Korpanty, Grzegorz, Derek G. Power, Conleth G. Murphy, Malcolm Kell, & John McCaffrey. (2010). Phyllodes tumor of the breast. Medical Oncology. 28(S1). 62–64. 7 indexed citations
20.
Murphy, Conleth G. & Shanu Modi. (2009). HER2 breast cancer therapies: a review. SHILAP Revista de lepidopterología. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Mayu Yunokawa Breakdown of academic impact, for papers by Henrik Roed Breakdown of academic impact, for papers by Sharad Ghamande Breakdown of academic impact, for papers by Volker Möbus Breakdown of academic impact, for papers by Antonio Febbraro Breakdown of academic impact, for papers by Andrea Michelotti Breakdown of academic impact, for papers by Kathy Han Breakdown of academic impact, for papers by Gregory Friberg Breakdown of academic impact, for papers by Akihiko Shimomura
Rankless by CCL
2026